Growing evidence suggests that current pathological indicators (e.g., estrogen receptor (ER), progesterone receptor(PR), human epidermal growth factor receptor 2(HER2), Ki67, and grading) have limitations for predicting breast cancer prognosis (30). Here, ERBB2 is linked to breast cancer.